Last 12 months
Inside the activity.
0 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2017 Filed May 4, 2017 18:16 UTC |
JACKSON SHIRLEY ADirector
|
Tax withholdingOrdinary Shares | 650 | $84.75 | $55,087.50 |
DisclosureSEC source: 0001127602-17-016837 · form4.xml · nonDerivative · entry 1 JACKSON SHIRLEY A · CIK 0001168019 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,148 Read SEC document |
| May 02, 2017 Filed May 4, 2017 18:22 UTC |
Powell Kendall JDirector
|
Tax withholdingOrdinary Shares | 650 | $84.75 | $55,087.50 |
DisclosureSEC source: 0001127602-17-016843 · form4.xml · nonDerivative · entry 1 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,182 Read SEC document |
| May 02, 2017 Filed May 4, 2017 19:54 UTC |
DONNELLY SCOTT CDirector
|
Tax withholdingOrdinary Shares | 650 | $84.75 | $55,087.50 |
DisclosureSEC source: 0001127602-17-016847 · form4.xml · nonDerivative · entry 1 DONNELLY SCOTT C · CIK 0001233158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,597 Read SEC document |
| May 02, 2017 Filed May 4, 2017 19:52 UTC |
ARNOLD CRAIGDirector
|
Tax withholdingOrdinary Shares | 650 | $84.75 | $55,087.50 |
DisclosureSEC source: 0001127602-17-016846 · form4.xml · nonDerivative · entry 1 ARNOLD CRAIG · CIK 0001188578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,385 Read SEC document |
| May 02, 2017 Filed May 4, 2017 19:56 UTC |
HOGAN RANDALL JDirector
|
Tax withholdingOrdinary Shares | 650 | $84.75 | $55,087.50 |
DisclosureSEC source: 0001127602-17-016848 · form4.xml · nonDerivative · entry 1 HOGAN RANDALL J · CIK 0001189049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,911 Read SEC document |
| May 02, 2017 Filed May 4, 2017 19:49 UTC |
ANDERSON RICHARD HDirector
|
Tax withholdingOrdinary Shares | 650 | $84.75 | $55,087.50 |
DisclosureSEC source: 0001127602-17-016845 · form4.xml · nonDerivative · entry 1 ANDERSON RICHARD H · CIK 0001200334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,310 Read SEC document |
| May 02, 2017 Filed May 4, 2017 18:18 UTC |
NABEL ELIZABETH GDirector
|
Tax withholdingOrdinary Shares | 650 | $84.75 | $55,087.50 |
DisclosureSEC source: 0001127602-17-016839 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,784 Read SEC document |
| May 01, 2017 Filed May 3, 2017 16:05 UTC |
OLEARY DENISE MDirector
|
GrantOrdinary Shares | 2,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016605 · form4.xml · nonDerivative · entry 1 OLEARY DENISE M · CIK 0001145159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,028 F1 · security: This balance increased by 515 shares due to exempt transactions such as dividend reinvestment. F2 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 01, 2017 Filed May 3, 2017 19:55 UTC |
JACKSON SHIRLEY ADirector
|
GrantOrdinary Shares | 2,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016596 · form4.xml · nonDerivative · entry 1 JACKSON SHIRLEY A · CIK 0001168019 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,797 F1 · security: This balance increased by 718 shares due to exempt transactions such as dividend reinvestment. F2 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 01, 2017 Filed May 3, 2017 20:06 UTC |
Powell Kendall JDirector
|
GrantOrdinary Shares | 2,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016608 · form4.xml · nonDerivative · entry 1 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,831 F1 · security: This balance increased by 366 shares due to exempt transactions such as dividend reinvestment. F2 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 01, 2017 Filed May 3, 2017 19:59 UTC |
DONNELLY SCOTT CDirector
|
GrantOrdinary Shares | 2,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016598 · form4.xml · nonDerivative · entry 1 DONNELLY SCOTT C · CIK 0001233158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,246 F1 · security: This balance increased by 90 shares due to exempt transactions. F2 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 01, 2017 Filed May 3, 2017 20:01 UTC |
ARNOLD CRAIGDirector
|
GrantOrdinary Shares | 2,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016601 · form4.xml · nonDerivative · entry 1 ARNOLD CRAIG · CIK 0001188578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,035 F1 · security: This balance increased by 13 shares due to exempt transactions such as dividend reinvestment. F2 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 01, 2017 Filed May 3, 2017 16:01 UTC |
Lenehan James TDirector
|
GrantOrdinary Shares | 2,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016600 · form4.xml · nonDerivative · entry 1 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,990 F1 · security: This balance increased 261 shares due to exempt transactions such as dividend reinvestment. F2 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 01, 2017 Filed May 3, 2017 19:57 UTC |
HOGAN RANDALL JDirector
|
GrantOrdinary Shares | 2,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016597 · form4.xml · nonDerivative · entry 1 HOGAN RANDALL J · CIK 0001189049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,561 F1 · security: This balance increased by 13 shares due to exempt transactions. F2 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 01, 2017 Filed May 3, 2017 20:28 UTC |
ANDERSON RICHARD HDirector
|
GrantOrdinary Shares | 2,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016621 · form4.xml · nonDerivative · entry 1 ANDERSON RICHARD H · CIK 0001200334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,959 F1 · security: This balance increased by 625 shares due to exempt transactions such as dividend reinvestment. F2 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 01, 2017 Filed May 3, 2017 16:08 UTC |
POZEN ROBERT CDirector
|
GrantOrdinary Shares | 2,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016611 · form4.xml · nonDerivative · entry 1 POZEN ROBERT C · CIK 0001278408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,615 F1 · security: This balance increased by 302 shares due to exempt transactions such as dividend reinvestment. F2 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 01, 2017 Filed May 3, 2017 19:52 UTC |
LEAVITT MICHAEL ODirector
|
GrantOrdinary Shares | 2,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016593 · form4.xml · nonDerivative · entry 1 LEAVITT MICHAEL O · CIK 0001536118 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,692 F1 · security: This balance increased by 201 shares due to exempt transactions such as dividend reinvestment. F2 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 01, 2017 Filed May 3, 2017 20:03 UTC |
NABEL ELIZABETH GDirector
|
GrantOrdinary Shares | 2,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016602 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,434 F1 · security: This balance increased by 48 shares due to exempt transactions such as dividend reinvestment. F2 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 18:07 UTC |
TEN HOEDT ROBEVP & President EMEA
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 11,117 | $0.00 Strike: $55.32 | $0.00 |
DisclosureSEC source: 0001127602-17-012558 · form4.xml · derivative · entry 9 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,514 Underlying: Ordinary Shares · 11,117 shares Expires 2023-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option to purchase 14,823 New Medtronic ordinary shares for $55.32 per share, which was partially vested at the effective time of the Merger, was received in the Merger and represents the conversion of 14,823 Medtronic common stock shares for $55.32 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 18:07 UTC |
TEN HOEDT ROBEVP & President EMEA
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,357 | $0.00 Strike: $62.76 | $0.00 |
DisclosureSEC source: 0001127602-17-012558 · form4.xml · derivative · entry 8 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,951 Underlying: Ordinary Shares · 10,357 shares Expires 2024-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option to purchase 20,714 New Medtronic ordinary shares for $62.76 per share, which was unvested at the effective time of the Merger, was received in the Merger and represents the conversion of 20,714 Medtronic common stock shares for $62.76 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 18:07 UTC |
TEN HOEDT ROBEVP & President EMEA
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 21,129 | $0.00 Strike: $38.81 | $0.00 |
DisclosureSEC source: 0001127602-17-012558 · form4.xml · derivative · entry 7 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,129 shares Expires 2022-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option to purchase 21,129 New Medtronic ordinary shares for $38.81per share, which was partially vested at the effective time of the Merger, was received in the Merger and represents the conversion of 21,129 Medtronic common stock shares for $38.81per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 18:07 UTC |
TEN HOEDT ROBEVP & President EMEA
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,154 | $0.00 Strike: $37.53 | $0.00 |
DisclosureSEC source: 0001127602-17-012558 · form4.xml · derivative · entry 6 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,154 shares Expires 2020-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 8,154 New Medtronic ordinary shares for $37.53 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 8,154 Medtronic common stock shares for $37.53 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 18:07 UTC |
TEN HOEDT ROBEVP & President EMEA
|
SaleOrdinary Shares | 50,757 | $81.58 | $4,140,593.64 |
DisclosureSEC source: 0001127602-17-012558 · form4.xml · nonDerivative · entry 5 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,238 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.301 to $82.098, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: This balance increased by 386 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 18:07 UTC |
TEN HOEDT ROBEVP & President EMEA
|
Exercise / conversionOrdinary Shares | 11,117 | $55.32 | $614,992.44 |
DisclosureSEC source: 0001127602-17-012558 · form4.xml · nonDerivative · entry 4 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 18:07 UTC |
TEN HOEDT ROBEVP & President EMEA
|
Exercise / conversionOrdinary Shares | 10,357 | $62.76 | $650,005.32 |
DisclosureSEC source: 0001127602-17-012558 · form4.xml · nonDerivative · entry 3 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 18:07 UTC |
TEN HOEDT ROBEVP & President EMEA
|
Exercise / conversionOrdinary Shares | 21,129 | $38.81 | $820,016.49 |
DisclosureSEC source: 0001127602-17-012558 · form4.xml · nonDerivative · entry 2 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 18:07 UTC |
TEN HOEDT ROBEVP & President EMEA
|
Exercise / conversionOrdinary Shares | 8,154 | $37.53 | $306,019.62 |
DisclosureSEC source: 0001127602-17-012558 · form4.xml · nonDerivative · entry 1 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 19:23 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $38.81 | $0.00 |
DisclosureSEC source: 0001127602-17-012155 · form4.xml · derivative · entry 3 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,338 Underlying: Ordinary Shares · 75,000 shares Expires 2022-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: This option to purchase 290,338 New Medtronic ordinary shares for $38.81 per share, which was partially vested at the effective time of the Merger, was received in the Merger and represents the conversion of 290,338 Medtronic common stock shares for $38.81 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 19:23 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
SaleOrdinary Shares | 95,000 | $82.82 | $7,868,014.00 |
DisclosureSEC source: 0001127602-17-012155 · form4.xml · nonDerivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,616 F1 · kind: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.594 to $83.19, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: This balance increased by 4700 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 19:23 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
Exercise / conversionOrdinary Shares | 75,000 | $38.81 | $2,910,750.00 |
DisclosureSEC source: 0001127602-17-012155 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 645,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 19:01 UTC |
HOGAN RANDALL JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,109 | $0.00 Strike: $27.38 | $0.00 |
DisclosureSEC source: 0001127602-17-010412 · form4.xml · derivative · entry 3 HOGAN RANDALL J · CIK 0001189049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,109 shares Expires 2017-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: In the Merger, Covidien options outstanding as of closing were converted into options to buy shares of New Medtronic. This option to purchase 15,109 New Medtronic ordinary shares for $27.38 per share was received in the Merger and represents the conversion of 10,521 Covidien ordinary shares for $39.32 per share, which were fully vested at the time of the Merger. The conversion ratio and exercise price was calculated according to the terms of the Transaction Agreement, which does not allow for options on fractional shares of New Medtronic. Other than as to the number of underlying shares and the exercise price, this New Medtronic stock option has the same terms and conditions as the original Covidien stock option. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 19:01 UTC |
HOGAN RANDALL JDirector
|
Exercise / conversionOrdinary Shares | 15,109 | $27.38 | $413,684.42 |
DisclosureSEC source: 0001127602-17-010412 · form4.xml · nonDerivative · entry 1 HOGAN RANDALL J · CIK 0001189049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance increased by 35 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 13:57 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 36,648 | $0.00 Strike: $62.76 | $0.00 |
DisclosureSEC source: 0001127602-17-010410 · form4.xml · derivative · entry 7 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,317 Underlying: Ordinary Shares · 36,648 shares Expires 2024-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option to purchase 73,296 New Medtronic ordinary shares for $62.76 per share, which was unvested at the effective time of the Merger, was received in the Merger and represents the conversion of 73,296 Medtronic common stock shares for $62.76 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 13:57 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 797 | $0.00 Strike: $62.76 | $0.00 |
DisclosureSEC source: 0001127602-17-010410 · form4.xml · derivative · entry 6 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,965 Underlying: Ordinary Shares · 797 shares Expires 2024-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option to purchase 1,594 ordinary shares of New Medtronic for $62.76 per share, which was unvested at the effective time of the Merger, was received in the Merger and represents the conversion of 1,594 Medtronic common stock shares for $62.76 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 13:57 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 14,871 | $0.00 Strike: $62.76 | $0.00 |
DisclosureSEC source: 0001127602-17-010410 · form4.xml · derivative · entry 5 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,762 Underlying: Ordinary Shares · 14,871 shares Expires 2024-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 29,743 New Medtronic ordinary shares for $62.76 per share, which was unvested at the effective time of the Merger, was received in the Merger and represents the conversion of 29,743 Medtronic common stock shares for $62.76 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 13:57 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
SaleOrdinary Shares | 52,316 | $82.33 | $4,307,019.33 |
DisclosureSEC source: 0001127602-17-010410 · form4.xml · nonDerivative · entry 4 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,929 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.30 to $82.41, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: This balance increased by 627 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 13:57 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionOrdinary Shares | 36,648 | $62.76 | $2,300,028.48 |
DisclosureSEC source: 0001127602-17-010410 · form4.xml · nonDerivative · entry 3 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 13:57 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionOrdinary Shares | 797 | $62.76 | $50,019.72 |
DisclosureSEC source: 0001127602-17-010410 · form4.xml · nonDerivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 13:57 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionOrdinary Shares | 14,871 | $62.76 | $933,303.96 |
DisclosureSEC source: 0001127602-17-010410 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 22:06 UTC |
ARNOLD CRAIGDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,109 | $0.00 Strike: $27.38 | $0.00 |
DisclosureSEC source: 0001127602-17-010244 · form4.xml · derivative · entry 3 ARNOLD CRAIG · CIK 0001188578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,109 shares Expires 2017-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: In the Merger, Covidien options outstanding as of closing were converted into options to buy shares of New Medtronic. This option to purchase 15,109 New Medtronic ordinary shares for $27.38 per share was received in the Merger and represents the conversion of 10,521 Covidien ordinary shares for $39.32 per share, which were fully vested at the time of the Merger. The conversion ratio and exercise price was calculated according to the terms of the Transaction Agreement, which does not allow for options on fractional shares of New Medtronic. Other than as to the number of underlying shares and the exercise price, this New Medtronic stock option has the same terms and conditions as the original Covidien stock option. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 22:06 UTC |
ARNOLD CRAIGDirector
|
Tax withholdingOrdinary Shares | 6,974 | $82.07 | $572,356.18 |
DisclosureSEC source: 0001127602-17-010244 · form4.xml · nonDerivative · entry 2 ARNOLD CRAIG · CIK 0001188578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,939 Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 22:06 UTC |
ARNOLD CRAIGDirector
|
Exercise / conversionOrdinary Shares | 15,109 | $27.38 | $413,684.42 |
DisclosureSEC source: 0001127602-17-010244 · form4.xml · nonDerivative · entry 1 ARNOLD CRAIG · CIK 0001188578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance increased by 35 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| March 01, 2017 Filed Mar 22, 2017 19:48 UTC Amendment |
ARNOLD CRAIGDirector
|
Tax withholdingOrdinary Shares | 6,981 | $82.07 | $572,930.67 |
DisclosureSEC source: 0001127602-17-012615 · form4a.xml · nonDerivative · entry 1 ARNOLD CRAIG · CIK 0001188578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,932 F1 · shares: This amount was amended from 6974 for an administrative correction of tax shares withheld. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 18:46 UTC |
Hanson Bryan CEVP, President, MITG
|
Tax withholdingOrdinary Shares | 1,751 | $78.88 | $138,118.88 |
DisclosureSEC source: 0001127602-17-007255 · form4.xml · nonDerivative · entry 1 Hanson Bryan C · CIK 0001524349 · EVP, President, MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,403 F1 · security: This balance increased by 569 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 14:41 UTC |
Lenehan James TDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 801 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001127602-17-001264 · form4.xml · derivative · entry 4 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 801 shares Expires 2017-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option to purchase 801 New Medtronic ordinary shares for $54.14 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 801 Medtronic common stock shares for $54.14 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 14:41 UTC |
Lenehan James TDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,586 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001127602-17-001264 · form4.xml · derivative · entry 3 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 801 Underlying: Ordinary Shares · 2,586 shares Expires 2017-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option to purchase 2,586 ordinary shares of New Medtronic for $54.14 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 2,586 Medtronic common stock shares for $54.14 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 14:41 UTC |
Lenehan James TDirector
|
Exercise / conversionOrdinary Shares | 801 | $54.14 | $43,366.14 |
DisclosureSEC source: 0001127602-17-001264 · form4.xml · nonDerivative · entry 2 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 14:41 UTC |
Lenehan James TDirector
|
Exercise / conversionOrdinary Shares | 2,586 | $54.14 | $140,006.04 |
DisclosureSEC source: 0001127602-17-001264 · form4.xml · nonDerivative · entry 1 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 17:29 UTC |
Ellis Gary LeeEVP & Global Ops and IT
|
GiftOrdinary Shares | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-000416 · form4.xml · nonDerivative · entry 1 Ellis Gary Lee · CIK 0001290170 · EVP & Global Ops and IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,718 F1 · security: This balance increased by 464 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| December 13, 2016 Filed Dec 14, 2016 15:57 UTC |
POZEN ROBERT CDirector
|
PurchaseOrdinary Shares | 13,660 | $73.21 | $999,983.03 |
DisclosureSEC source: 0001127602-16-069999 · form4.xml · nonDerivative · entry 1 POZEN ROBERT C · CIK 0001278408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,223 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $73.13 to $73.25, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Form 4. F2 · balance_after: This balance increased by 137 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.